MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524531 | Name: BMY-21502

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMY-21502 is an identified potential cognitive enhancer, an nootropic agent. In studies it has shown to protect rodents from ECS-induced amnesia in a step-down passive avoidance task.

Chemical Structure

BMY-21502
CAS#123259-91-6

Theoretical Analysis

MedKoo Cat#: 524531

Name: BMY-21502

CAS#: 123259-91-6

Chemical Formula: C15H19F3N4O

Exact Mass: 328.1511

Molecular Weight: 328.33

Elemental Analysis: C, 54.87; H, 5.83; F, 17.36; N, 17.06; O, 4.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bmy 21502; Bmy21502; Bmy-21502; Bms-181168; Bms 181168; Bms181168.
IUPAC/Chemical Name
1-((1-(2-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)methyl)pyrrolidin-2-one
InChi Key
KEWFMWJJMGQBAN-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H19F3N4O/c16-15(17,18)14-19-6-3-12(20-14)21-8-4-11(5-9-21)10-22-7-1-2-13(22)23/h3,6,11H,1-2,4-5,7-10H2
SMILES Code
N1(C(CCC1)=O)CC1CCN(CC1)c1nc(ncc1)C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 328.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull. 1998;34(3):391-7. PubMed PMID: 9803773. 2: Srinivas N, Kaul S. Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs. Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):61-5. PubMed PMID: 9625274. 3: Shrotriya RC, Cutler NR, Sramek JJ, Veroff AE, Hironaka DY. Efficacy and safety of BMY 21,502 in Alzheimer disease. Ann Pharmacother. 1996 Dec;30(12):1376-80. PubMed PMID: 8968446. 4: Saletu B, Schulz H, Herrmann WM, Anderer P, Shrotriya RC, Vanbrabant E. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Pharmacopsychiatry. 1994 Sep;27(5):189-97. PubMed PMID: 7838889. 5: Bandoli G, Dolmella A, Nicolini M, Tisato F. X-ray, NMR, and theoretical studies of the nootropic agent BMY-21502, a pyrrolidinone derivative. J Pharm Sci. 1994 Jun;83(6):878-82. PubMed PMID: 9120825. 6: Pierce JE, Smith DH, Eison MS, McIntosh TK. The nootropic compound BMY-21502 improves spatial learning ability in brain injured rats. Brain Res. 1993 Oct 8;624(1-2):199-208. PubMed PMID: 8252392. 7: Cutler NR, Shrotriya RC, Sramek JJ, Veroff AE, Seifert RD, Reich LA, Hironaka DY. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Ann N Y Acad Sci. 1993 Sep 24;695:332-6. PubMed PMID: 8239308. 8: Amano M, Goto A, Takahashi N, Hasegawa T, Nabeshima T. Effects of BMY-21502 on anoxia in mice. Jpn J Pharmacol. 1993 Mar;61(3):157-63. PubMed PMID: 8483292. 9: Lindner MD, Gribkoff VK. Effects of oral BMY 21502 on Morris water task performance in 16-18 month old F-344 rats. Psychopharmacology (Berl). 1992;107(4):485-8. PubMed PMID: 1603891. 10: Means LW, Comer TR, Moore R. BMY 21502 and piracetam facilitate performance of two-choice win-stay water-escape in normal rats. J Neural Transm Gen Sect. 1991;85(2):109-16. PubMed PMID: 1930875. 11: Woodruff-Pak DS, Sasse DK, Coffin JM, Haunton-Kreps M, Moon SL. Effect of BMY 21502 on classical conditioning of the eyeblink response in young and older rabbits. Ann N Y Acad Sci. 1991;640:284-9. PubMed PMID: 1776753. 12: Gribkoff VK, Bauman LA, VanderMaelen CP. A 1-heteroaryl-4-piperidinyl-methyl pyrrolidinone, BMY 21502, delays the decay of hippocampal synaptic potentiation in vitro. Neuropharmacology. 1990 Nov;29(11):1001-9. PubMed PMID: 2087253. 13: Fitten LJ, Perryman KM, Hanna JA, Menon MK. Effect of BMY 21502 on acquisition of shape discrimination and memory retention in monkey. Pharmacol Biochem Behav. 1990 Mar;35(3):553-6. PubMed PMID: 2339147.

View History

BMT-124110

BMT-124110

Azido-PEG16-acid

Azido-PEG16-acid

Azide-PEG16-alcohol

Azide-PEG16-alcohol